News | February 15, 2021
Glenmark Q3 FY21 net profit up 30% at Rs 248 Cr
The jump in profit is due to the better performance of the API business.
The jump in profit is due to the better performance of the API business.
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
According to IQVIA sales data for the 12 month period ending December 2020, the Cleocin T Gel, 1% market achieved annual sales of approximately $73.8 million.
Be One is a 100% Ayurvedic health and wellness supplement.
Tavaborole Topical Solution, 5%, is an oxaborole antifungal.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Subscribe To Our Newsletter & Stay Updated
